JP2010500293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500293A5 JP2010500293A5 JP2009523120A JP2009523120A JP2010500293A5 JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5 JP 2009523120 A JP2009523120 A JP 2009523120A JP 2009523120 A JP2009523120 A JP 2009523120A JP 2010500293 A5 JP2010500293 A5 JP 2010500293A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101150109738 Ptger4 gene Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 0 CC(NS(*)(=O)=O)=O Chemical compound CC(NS(*)(=O)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83725206P | 2006-08-11 | 2006-08-11 | |
| US60/837,252 | 2006-08-11 | ||
| PCT/CA2007/001404 WO2008017164A1 (en) | 2006-08-11 | 2007-08-10 | Thiophenecarboxamide derivatives as ep4 receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500293A JP2010500293A (ja) | 2010-01-07 |
| JP2010500293A5 true JP2010500293A5 (enExample) | 2010-09-16 |
| JP5259592B2 JP5259592B2 (ja) | 2013-08-07 |
Family
ID=39032586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523120A Expired - Fee Related JP5259592B2 (ja) | 2006-08-11 | 2007-08-10 | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8969394B2 (enExample) |
| EP (1) | EP2054401B1 (enExample) |
| JP (1) | JP5259592B2 (enExample) |
| CN (1) | CN101541778B (enExample) |
| AU (1) | AU2007283404B2 (enExample) |
| CA (1) | CA2660133C (enExample) |
| ES (1) | ES2421453T3 (enExample) |
| WO (1) | WO2008017164A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172447A4 (en) * | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| JP2010535765A (ja) * | 2007-08-09 | 2010-11-25 | メルク・シャープ・エンド・ドーム・コーポレイション | チオフェンカルボキサミド誘導体の製造方法 |
| ES2518919T3 (es) * | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| CN102149384B (zh) * | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| CA2789665C (en) * | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| WO2012039972A1 (en) | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| KR20150130404A (ko) * | 2013-03-19 | 2015-11-23 | 에스크엣 인크. | 연골질환 치료에서의 ep4 수용체 길항제의 용도 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| CN105431416B (zh) | 2013-06-12 | 2019-01-08 | 科研制药株式会社 | 4-炔基咪唑衍生物和含有其作为有效成分的药物 |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| SG11201609770TA (en) * | 2014-05-23 | 2016-12-29 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of cancer |
| CA2953218A1 (en) * | 2014-06-06 | 2015-12-10 | Allergan, Inc. | Ep4 agonists as therapeutic compounds |
| CN105037186A (zh) * | 2015-06-17 | 2015-11-11 | 苏州敬业医药化工有限公司 | 一种氨甲苯酸的制备方法 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| US10202415B1 (en) | 2017-10-19 | 2019-02-12 | King Saud University | Method of synthesizing of 3-oxolupenal nanoparticles |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
| IL296007B2 (en) | 2020-03-04 | 2026-03-01 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Synthesis of a novel EP4 antibody and use for cancer and inflammation |
| EP4200281A4 (en) * | 2020-08-18 | 2024-09-25 | Hutchison Medipharma Limited | PYRIMIDINONE COMPOUNDS AND THEIR USES |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| CZ20031903A3 (cs) * | 2001-01-31 | 2004-07-14 | Pfizer Products Inc. | Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4 |
| WO2004099127A1 (en) * | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| CA2536870C (en) * | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP2007533723A (ja) * | 2004-04-20 | 2007-11-22 | ファイザー・プロダクツ・インク | α２δリガンドを含む組合せ |
| AU2005238291A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| KR20070006890A (ko) * | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물 |
| WO2005116010A1 (en) * | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
-
2007
- 2007-08-10 AU AU2007283404A patent/AU2007283404B2/en not_active Ceased
- 2007-08-10 ES ES07815782T patent/ES2421453T3/es active Active
- 2007-08-10 WO PCT/CA2007/001404 patent/WO2008017164A1/en not_active Ceased
- 2007-08-10 JP JP2009523120A patent/JP5259592B2/ja not_active Expired - Fee Related
- 2007-08-10 US US12/309,941 patent/US8969394B2/en active Active
- 2007-08-10 CN CN200780037574.4A patent/CN101541778B/zh not_active Expired - Fee Related
- 2007-08-10 CA CA2660133A patent/CA2660133C/en not_active Expired - Fee Related
- 2007-08-10 EP EP07815782.3A patent/EP2054401B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527331A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| JP2013056886A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| EA022527B1 (ru) | 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ | |
| JP2008513496A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| BR112015018882B1 (pt) | Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo | |
| JP2010523476A5 (enExample) | ||
| JP2013512277A5 (enExample) | ||
| JP2012502927A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2011523952A5 (enExample) | ||
| JP2013511556A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2013521301A5 (enExample) | ||
| JP2018521121A5 (enExample) | ||
| JP2018513832A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2011523412A5 (enExample) |